GM1 and GM2 Gangliosidosis PROspective Neurological Disease TrajectOry Study (PRONTO)

NCT05109793 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 31

Last updated 2025-09-29

No results posted yet for this study

Summary

The study aims to characterize prospectively longitudinal progression of neurological domains in GM1 and GM2 Gangliosidosis patients with high-quality standards (GCP compliant).

Conditions

  • GM1 Gangliosidosis
  • Sandhoff Disease
  • Tay-Sachs Disease

Sponsors & Collaborators

  • Azafaros A.G.

    lead INDUSTRY

Eligibility

Min Age
2 Years
Max Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-22
Primary Completion
2025-09-16
Completion
2025-09-16

Countries

  • United States
  • Brazil
  • France
  • Germany
  • Italy
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05109793 on ClinicalTrials.gov